Lupus News

Deucravacitinib is “very likely to be the best” targeted small-molecule drug for the treatment of systemic lupus erythematosus, according to data published in Arthritis Research & Therapy.

New definitions of remission specific to childhood systemic lupus erythematosus promote cessation of corticosteroids and could enable combined child-adult treat-to-target studies, according to an analysis published in Clinical Immunology.

CLEVELAND — While new treatments for cutaneous lupus are on the horizon, sunscreen remains the best way to offset effects, according to J. Michelle Kahlenberg, MD, PhD.

Skin disease manifestations in systemic lupus erythematosus do not have an impact on disease severity, according to a study.

Proteinuria levels are not predictive of membranous lupus nephritis vs. proliferative lupus nephritis, according to data published in Rheumatology.

The SLE Severe Infection Score-Revised, an updated score for predicting severe infections in systemic lupus erythematosus, is more accurate and feasible than the prior version, according to data published in Lupus Science & Medicine.

The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.

The FDA has approved a Benlysta autoinjector for children aged 5 years and older with systemic lupus erythematosus, enabling at-home administration for the first time, according to a press release from the manufacturer.

DESTIN, Fla. — When choosing between biologic drugs for systemic lupus erythematosus, it is important to know the “ideal patient profile” each is best suited for, according to a speaker at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Ongoing, frank discussions about reproductive health with patients of childbearing age is critical to safe pregnancy outcomes, according to a presenter at the Congress of Clinical Rheumatology East.